Notes:  December 28, 2017 -- Sorrento Tech, Inc. (the “Company”) filed a Certificate of Dissolution with the Secretary of State of the State of Delaware (the “Certificate of Dissolution”). The Certificate of Dissolution became effective at 5:00 p.m. Eastern Standard Time on December 28, 2017 (the “Effective Time”) and provides for the dissolution of the Company under the Delaware General Corporation Law. In addition, as of the Effective Time, the Company closed its stock transfer books and discontinued recording, on its stock transfer books, transfers of the Company’s common stock occurring after such date. As previously reported, on December 19, 2017, the Company filed with the Securities and Exchange Commission (the “SEC”) and NASDAQ a Form 25 relating to the delisting of the Stock. The delisting of the Company’s common stock was effective at the open of business on December 29, 2017. The Company intends to file a Form 15 with the SEC to voluntarily effect deregistration of its securities under the Securities Exchange Act of 1934, as amended. The Company expects that its obligation to file periodic and current reports, such as Annual Reports on Form 10-K, Quarterly Reports on Form 10-Q and Current Reports on Form 8-K, will be suspended upon the filing of the Form 15. ________________ November 1, 2017 -- pursuant to the terms of the Asset Purchase Agreement, dated August 16, 2017, as amended (the “Agreement”) by and between Roka Bioscience, Inc., a Delaware corporation (the “Company”) and Rokabio, Inc., the Company closed the sale of substantially all of the assets of the Company, excluding its Accounts Receivables (as defined in the Agreement), totaling $856,000 as of October 31, 2017, (the “Asset Sale”) in an all-cash transaction for an aggregate purchase price of $16,500,000. _______________October 12, 2016 -- Roka Bioscience, Inc (ROKA) will effect a one-for-ten (1-10) reverse split of its Common Stock. The CUSIP number will change to 775431208.

Company's Online Information Links

HOME PAGE:     http://www.rokabio.com/
Company's Investor Relations Information	Goto Investor Relations Information
Company's Online News Releases	Goto News Releases
Online Company Profile	Goto Online Profile

Company's Online SEC EDGAR Filings

Company's SEC EDGAR Filings

Goto SEC Filings

Company's Email Address Links

Email Address	ssobieski@rokabio.com
Email Contact Form on Website	Goto Email Form

Address and Phone Numbers

Address:   20 Independence Boulevard, Warren, NJ 07059
Main Phone Number	908-605-4700
Fax Number	Not Available
Investor Contact (CFO)   Steve Sobieski	908-605-4621
Toll Free Phone Number	855-765-2246

CEO - Paul G. Thomas

CFO - Steve Sobieski